A drug for constipation can treat chronic renal failure

Researchers at the Japanese University of Tuoko announced the results of the first clinical trial showing that drug Lucroston – mainly known as a drug for the treatment of chronic constipation – can improve kidney function in patients with chronic kidney disease. Lubroston is used to treat unknown unknown constipation, constipation associated with irritable bowel syndrome in women, constipation due to the use of opioid pain relievers, the drug was developed by the US “sukambo” medicine business, and the approval of the US food and drug administration in 2006. General side effect. Chronic kidney disease is one of the most important health challenges worldwide, as it affects hundreds of millions of people, and in many cases leading to renal failure that requires regular bloody wash sessions to survive. We noticed that constipation is a common offer among chronic kidney patients, and we began to wonder about the connection between them. The lead author of the study of Takaki Abe of the Faculty of Medicine at the University of Tuoko and despite the severity and spread of the disease, there is no effective medicine that can directly improve the kidney function, but the treatment is limited to the control of symptoms and reducing complications. “We have noticed that constipation is a common representation between chronic kidney patients, and we began to wonder about the link between them. It turned out to us that constipation caused an imbalance in the intestinal microbes, and it worsened the decline of the kidneys. Based on this hypothesis, the team performed the so-called the Lubi ACD experience, an experiment from the second phase that included 9 medical centers in Japan, and 150 patients with chronic kidney disorders participated in a medium degree. Patients were divided into groups that received different doses of Luboston -from 8 micrograms or 16 micrograms and another group that received a false medicine, and the results showed that the decline in kidney function has significantly delayed in patients who took Lucroston, and on the dose dependent. According to the study published in the Journal “Science Advanbas”, the proposed mechanism works on the intestinal axis – the mechanism in interconnected stages, as Lubroston begins – which is the drug that improves the movement and empties it – by adjusting the inner colon and By increasing Fluid Secretion and Stimulating Intestinal Transit, which changes the composition of the microbium, and reduces its iMbalance accompanying the chronic contipation of many patients from kidney insufficiency. Recommendations to protect from kidney failure to measure blood pressure regularly and treat the height early. Reducing salt and sodium in foods and replacing it with natural herbs and spices. Avoid sodium and phosphoric foods, due to their damage to the kidneys and bones. Drink enough water (about two liters a day) to keep the moisture of the kidneys and prevent gravel. Sleep enough hours to ensure regular kidney function. Reducing red meat and excess protein to avoid blood acid. Mates in eating sugars and sweetened drinks. Avoid excessive painkillers and anti -inflammatory drugs, and keep only on the recommended doses. This shift in bacterial balance is preferred to grow useful stems, and increases the production of polyethamines, of which the spymenidine is; These are cellular signals known as their role in improving the efficiency of mitochondria by supporting energy balance, reducing oxidative stress and improving cellular maintenance operations. With the improved performance of mitochondria in the kidney cells, the kidney can withstand inflammatory and toxic pressure, thus delaying the rate of damage, and general inflammatory signals decrease – that is, the cure provides a double protective impact that combines the recovery of cellular energy and ignition of the curb. Although this experience is the first in the world to show a concrete medicinal benefit in improving chronic kidney function, researchers claim that the road is still long, as the next step will be to do a broader clinical trial – the third phase – including a larger number of patients to confirm the results. The team also plans to determine important indicators that help predict the extent to which each patient benefits from the treatment, with the aim of developing personal treatment plans.